Gas Plasma-Conditioned Ringer's Lactate Enhances the Cytotoxic Activity of Cisplatin and Gemcitabine in Pancreatic Cancer In Vitro and In Ovo.
ROS
anticancer drugs
combination therapy
kINPen
plasma medicine
reactive oxygen and nitrogen species
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Jan 2020
02 Jan 2020
Historique:
received:
28
11
2019
revised:
19
12
2019
accepted:
27
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
8
1
2020
Statut:
epublish
Résumé
Pancreatic cancer is one of the most aggressive tumor entities. Diffuse metastatic infiltration of vessels and the peritoneum restricts curative surgery. Standard chemotherapy protocols include the cytostatic drug gemcitabine with limited efficacy at considerable toxicity. In search of a more effective and less toxic treatment modality, we tested in human pancreatic cancer cells (MiaPaca and PaTuS) a novel combination therapy consisting of cytostatic drugs (gemcitabine or cisplatin) and gas plasma-conditioned Ringer's lactate that acts via reactive oxygen species. A decrease in metabolic activity and viability, change in morphology, and cell cycle arrest was observed in vitro. The combination treatment was found to be additively toxic. The findings were validated utilizing an in ovo tumor model of solid pancreatic tumors growing on the chorion-allantois membrane of fertilized chicken eggs (TUM-CAM). The combination of the drugs (especially cisplatin) with the plasma-conditioned liquid significantly enhanced the anti-cancer effects, resulting in the induction of cell death, cell cycle arrest, and inhibition of cell growth with both of the cell lines tested. In conclusion, our novel combination approach may be a promising new avenue to increase the tolerability and efficacy of locally applied chemotherapeutic in diffuse metastatic peritoneal carcinomatosis of the pancreas.
Identifiants
pubmed: 31906595
pii: cancers12010123
doi: 10.3390/cancers12010123
pmc: PMC7017174
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 03Z22DN11
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Am J Gastroenterol. 2004 Mar;99(3):492-501
pubmed: 15056091
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
PLoS One. 2013 May 21;8(5):e64498
pubmed: 23704990
Cytotechnology. 2015 Jan;67(1):13-7
pubmed: 24242827
Cancers (Basel). 2019 Jul 22;11(7):
pubmed: 31336648
Biol Chem. 2018 Dec 19;400(1):39-62
pubmed: 30044757
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
Cancers (Basel). 2019 Aug 23;11(9):
pubmed: 31450811
Drug Des Devel Ther. 2016 Jun 13;10:1961-72
pubmed: 27358556
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
J Surg Oncol. 2010 Nov 1;102(6):663-70
pubmed: 20721959
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Neoplasia. 2010 Sep;12(9):740-7
pubmed: 20824050
In Vivo. 2000 Jan-Feb;14(1):183-8
pubmed: 10757076
Ann Surg Oncol. 2017 May;24(5):1188-1194
pubmed: 28058557
PLoS One. 2012;7(12):e52653
pubmed: 23300736
Sci Rep. 2016 Nov 08;6:36282
pubmed: 27824103
In Vivo. 2019 Jul-Aug;33(4):1011-1026
pubmed: 31280189
Oxid Med Cell Longev. 2019 Sep 3;2019:3873928
pubmed: 31565150
Oncogene. 2016 Jul 28;35(30):3976-85
pubmed: 26686091
Sci Rep. 2019 Mar 11;9(1):4112
pubmed: 30858416
Cancer Cell. 2010 Jun 15;17(6):574-83
pubmed: 20541702
Biomed Pharmacother. 2019 Feb;110:518-527
pubmed: 30530287
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Cancers (Basel). 2018 Feb 11;10(2):
pubmed: 29439461
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
pubmed: 19478820
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Ann Surg Oncol. 2018 Jan;25(1):299-307
pubmed: 29139022
Sci Rep. 2017 Aug 16;7(1):8319
pubmed: 28814809
Cell Death Dis. 2018 Dec 5;9(12):1179
pubmed: 30518936
Ann Surg Oncol. 2013 Oct;20(11):3497-503
pubmed: 23780382
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancers (Basel). 2019 Oct 19;11(10):
pubmed: 31635070
Eur J Cancer. 2013 Feb;49(3):593-603
pubmed: 22989511
Arch Biochem Biophys. 2018 Oct 15;656:19-30
pubmed: 30170003
Sci Rep. 2016 Feb 03;6:20332
pubmed: 26838306
Ann Surg Oncol. 2018 Aug;25(8):2159-2164
pubmed: 29423664
Clin Cancer Res. 2003 Oct 15;9(13):5000-8
pubmed: 14581375
Free Radic Biol Med. 2000 Aug;29(3-4):222-30
pubmed: 11035250
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cancers (Basel). 2019 Jun 18;11(6):
pubmed: 31216715
Cancer. 2015 Aug 1;121(15):2586-93
pubmed: 25872978
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Biochem Biophys Res Commun. 2016 Jan 22;469(4):1075-82
pubmed: 26740178
Pleura Peritoneum. 2018 Dec 18;3(4):20180124
pubmed: 30911668
Anticancer Res. 2018 Oct;38(10):5655-5663
pubmed: 30275184
Lancet. 2001 Nov 10;358(9293):1576-85
pubmed: 11716884
Pharmacol Res. 2016 Apr;106:27-36
pubmed: 26804248
World J Surg Oncol. 2016 Feb 29;14:59
pubmed: 26927942
Pancreas. 2013 Apr;42(3):511-5
pubmed: 23462324
Cancers (Basel). 2018 Oct 23;10(11):
pubmed: 30360539
Nature. 2006 Nov 30;444(7119):633-7
pubmed: 17136093
Sci Rep. 2019 Jan 24;9(1):634
pubmed: 30679720
Br J Cancer. 2016 Feb 16;114(4):435-43
pubmed: 26882067
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26
pubmed: 30341417